Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Investing.com - H.C. Wainwright raised its price target on Soleno Therapeutics Inc. (NASDAQ:SLNO) to $110.00 from $100.00 on Monday, while maintaining a Buy rating on the stock. Currently trading at $71.63, SLNO has seen a -16.48% decline over the past week, though InvestingPro data shows an impressive 49% gain over the past six months.
The price target increase comes despite a recent Citizen Petition filed with the FDA by Scorpion Capital late last week, which called for the withdrawal of Soleno’s sole marketed product, VYKAT XR, approved earlier this year for Prader-Willi Syndrome (PWS). According to InvestingPro analysis, the company maintains strong financial health with a current ratio of 15.13, indicating robust liquidity to weather regulatory challenges.
H.C. Wainwright expressed confidence that the petition would not succeed, citing the "extensive clinical assessment" conducted before VYKAT XR’s approval and the drug’s "compelling risk-benefit profile" for PWS patients. The firm also noted that native diazoxide has been used for years to manage PWS symptoms.
The research firm acknowledged VYKAT XR’s documented side effects, including hyperglycemia, edema, and hypertrichosis, but stated these issues "can be readily managed." The analysis suggested prescribers might show hesitation only when considering the drug for PWS patients who also have diabetes.
H.C. Wainwright further pointed out that over 80% of Citizen Petitions filed since 2001 have been denied or failed to receive an FDA response, suggesting limited likelihood of market withdrawal for VYKAT XR.
In other recent news, Soleno Therapeutics reported its earnings for the second quarter of 2025, surpassing expectations with notable revenue results. The company posted revenue of $32.7 million, significantly exceeding the anticipated $15.35 million, resulting in a surprise of 113.03%. Earnings per share were reported at -$0.09, which was a substantial improvement over the forecasted -$0.64. Following these strong results, Stifel raised its price target for Soleno Therapeutics to $118, citing an "excellent start" for the company’s Vykat launch. Similarly, Guggenheim increased its price target to $106, maintaining a Buy rating due to robust Vykat sales. Both firms highlighted encouraging dynamics in demand, prescribers, and payers. Soleno’s reported sales of $32.7 million were within the preannounced range and exceeded earlier consensus estimates. These developments reflect positively on the company’s recent performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.